Gabriela Smit

CRS:

BJMC

Role:

Administrative and Finance

Position:

Senior Research Service Analyst

Email:

gsmit1@jhmi.edu

Ms. Smit is Fiscal Operations Manager at the Johns Hopkins Center for Clinical Global Health Education. She is an experienced financial analyst with more than 2 decades of experience in finance and accounting and more than a decade of experience at Johns Hopkins University, where she has developed and managed federal and non-federal grants and contracts.
 
While at the CCGHE, she has assembled and managed several international teams of investigators from a number of institutions, including JHU, BJGMC (Lakshya, India), UVRI (Rakai, Uganda), and the National Institute for Research in Tuberculosis (Chennai, India). Ms. Smit provided strategic financial and administrative input to support the new JHU entities in India (JHIPL and JHIF). She manages all financial activities within the US, India and is the key contact for JHU-India collaborations with the NIH Grant Office, the JHU Central Administration, and the JHU SOM Office of Research Administration and Business Office.  In October 2016, she received the Johns Hopkins Department of Medicine Staff Recognition Award for outstanding service. Ms. Smit received a Bachelor of Science degree in Finance and Accounting from Babes-Bolyai University of Cluj-Napoca, Romania

Categories

Leadership Committees
CRS
Roles

Clinical Trials

A5361s: Pitavastatin to REduce Physical Function Impairment...

A5361s is a prospective study to determine the effects of pitavastatin on physical function. The study will enroll participants...

Read More

A5342: Evaluating the Safety, Tolerability, and Effect of a...

The purpose of this study is to evaluate the safety, tolerability, and effect of an experimental human monoclonal antibody...

Read More

A5332: Randomized Trial to Prevent Vascular Events in HIV...

REPRIEVE (A5332) is a large double-blind, randomized, placebo-controlled study of pitavastatin or placebo for about 72 months....

Read More

A5225: Phase I/II Dose-Finding Study of High-Dose...

A5225/HiFLAC is a Phase I/II dose escalation and validation study of the safety, tolerability, and therapeutic effect of an...

Read More

A5300/P2003: PHOENIx Feasibility Study

Study of MDR TB Cases and Their Household Contacts: Operational Feasibility to Inform PHOENIx Trial Design

Read More